New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only...

Related Keywords

United States ,Americans ,American ,Craig Stoltz ,Prnewswire Johnson ,Lloyd Miller ,Laura Ferris ,Janssen Research Development ,Janssen Biotech Inc ,Everyday Health ,American Academy Of Dermatology ,University Of Pittsburgh ,Exchange Commission ,National Psoriasis Foundation ,None Of Janssen Research Development ,Johnson ,Protagonist Therapeutics Inc ,American Academy ,Psoriasis Area ,Severity Index ,Global Assessment ,New England Journal ,Protagonist Therapeutics ,Janssen Biotech ,Vice President ,Immunodermatology Disease Area Leader ,Innovative Medicine ,Private Securities Litigation Reform Act ,Janssen Research ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Long Term Extension ,Dose Ranging Study ,Moderate To Severe Plaque Psoriasis ,Accessed March ,Long Term Extension Study ,Accessed Marc ,Serum Samples ,Plaque Psoriasis ,Inflammatory Bowel ,